BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 35771546)

  • 21. Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer.
    Kavanagh JJ; Levenback CF; Ramirez PT; Wolf JL; Moore CL; Jones MR; Meng L; Brown GL; Bast RC
    J Hematol Oncol; 2010 Mar; 3():9. PubMed ID: 20222977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study).
    Perez-Fidalgo JA; Cortés A; Guerra E; García Y; Iglesias M; Bohn Sarmiento U; Calvo García E; Manso Sánchez L; Santaballa A; Oaknin A; Redondo A; Rubio MJ; González-Martín A
    ESMO Open; 2021 Aug; 6(4):100212. PubMed ID: 34329939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer.
    Lawrie TA; Rabbie R; Thoma C; Morrison J
    Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD010482. PubMed ID: 24142521
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma.
    Ichikawa R; Torii Y; Oe S; Kawamura K; Kato R; Hasegawa K; Udagawa Y
    Arch Gynecol Obstet; 2014 Nov; 290(5):979-84. PubMed ID: 24798935
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.
    Monk BJ; Ghatage P; Parekh T; Henitz E; Knoblauch R; Matos-Pita AS; Nieto A; Park YC; Cheng PS; Li W; Favis R; Ricci D; Poveda A
    Ann Oncol; 2015 May; 26(5):914-920. PubMed ID: 25722380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.
    del Carmen MG; Micha J; Small L; Street DG; Londhe A; McGowan T
    Gynecol Oncol; 2012 Sep; 126(3):369-74. PubMed ID: 22659190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
    Pignata S; Lorusso D; Joly F; Gallo C; Colombo N; Sessa C; Bamias A; Salutari V; Selle F; Frezzini S; De Giorgi U; Pautier P; Bologna A; Orditura M; Dubot C; Gadducci A; Mammoliti S; Ray-Coquard I; Zafarana E; Breda E; Favier L; Ardizzoia A; Cinieri S; Largillier R; Sambataro D; Guardiola E; Lauria R; Pisano C; Raspagliesi F; Scambia G; Daniele G; Perrone F;
    Lancet Oncol; 2021 Feb; 22(2):267-276. PubMed ID: 33539744
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adverse Event Profile by Folate Receptor Status for Vintafolide and Pegylated Liposomal Doxorubicin in Combination, Versus Pegylated Liposomal Doxorubicin Alone, in Platinum-Resistant Ovarian Cancer: Exploratory Analysis of the Phase II PRECEDENT Trial.
    Herzog TJ; Kutarska E; Bidzińsk M; Symanowski J; Nguyen B; Rangwala RA; Naumann RW
    Int J Gynecol Cancer; 2016 Nov; 26(9):1580-1585. PubMed ID: 27654255
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer.
    Fuh KC; Bookman MA; Liu JF; Coleman RL; Herzog TJ; Thaker PH; Monk BJ; Anderson R; McIntyre G; Rangwala R; Moore KN
    Gynecol Oncol; 2021 Nov; 163(2):254-261. PubMed ID: 34474927
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study.
    Banerjee S; Oza AM; Birrer MJ; Hamilton EP; Hasan J; Leary A; Moore KN; Mackowiak-Matejczyk B; Pikiel J; Ray-Coquard I; Trask P; Lin K; Schuth E; Vaze A; Choi Y; Marsters JC; Maslyar DJ; Lemahieu V; Wang Y; Humke EW; Liu JF
    Ann Oncol; 2018 Apr; 29(4):917-923. PubMed ID: 29401246
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study.
    Runnebaum IB; Reichert D; Ringsdorf U; Kuther M; Hesse T; Sehouli J; Wimberger P
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1185-1195. PubMed ID: 29623421
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial.
    Poveda A; Vergote I; Tjulandin S; Kong B; Roy M; Chan S; Filipczyk-Cisarz E; Hagberg H; Kaye SB; Colombo N; Lebedinsky C; Parekh T; Gómez J; Park YC; Alfaro V; Monk BJ
    Ann Oncol; 2011 Jan; 22(1):39-48. PubMed ID: 20643862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Maintenance of pegylated liposomal doxorubicin/carboplatin in patients with advanced ovarian cancer: randomized study of an Asian Gynecologic Oncology Group.
    Lai CH; Vallikad E; Lin H; Yang LY; Jung SM; Liu HE; Ou YC; Chou HH; Lin CT; Huang HJ; Huang KG; Qiu J; Hung YC; Wu TI; Chang WY; Tan KT; Lin CY; Chao A; Chang CJ
    J Gynecol Oncol; 2020 Jan; 31(1):e5. PubMed ID: 31788995
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of Pegylated Liposomal Doxorubicin in Low-Grade Serous Ovarian Carcinoma.
    Rose PG; Radeva M; Michener CM; Link N; Adbul-Karim F
    Int J Gynecol Cancer; 2017 Jun; 27(5):907-911. PubMed ID: 28498259
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer.
    Vergote I; Schilder RJ; Pippitt CH; Wong S; Gordon AN; Scudder S; Kridelka F; Dirix L; Leach JW; Ananda S; Nanayakkara N; Melara R; Bass MB; Litten J; Adewoye H; Wenham RM
    Gynecol Oncol; 2014 Oct; 135(1):25-33. PubMed ID: 25019569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer.
    Verschraegen CF; Czok S; Muller CY; Boyd L; Lee SJ; Rutledge T; Blank S; Pothuri B; Eberhardt S; Muggia F
    Ann Oncol; 2012 Dec; 23(12):3104-3110. PubMed ID: 22851407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer.
    Kim KH; Jelovac D; Armstrong DK; Schwartz B; Weil SC; Schweizer C; Alvarez RD
    Gynecol Oncol; 2016 Feb; 140(2):210-4. PubMed ID: 26644263
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adipose tissue area is a predictive biomarker for the efficacy of pegylated liposomal doxorubicin in platinum-refractory/resistant ovarian cancer.
    Yoshida H; Fujiwara K
    Cancer Med; 2023 Jul; 12(13):14196-14206. PubMed ID: 37184128
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis.
    Monk BJ; Herzog TJ; Kaye SB; Krasner CN; Vermorken JB; Muggia FM; Pujade-Lauraine E; Park YC; Parekh TV; Poveda AM
    Eur J Cancer; 2012 Oct; 48(15):2361-8. PubMed ID: 22541893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
    Pujade-Lauraine E; Wagner U; Aavall-Lundqvist E; Gebski V; Heywood M; Vasey PA; Volgger B; Vergote I; Pignata S; Ferrero A; Sehouli J; Lortholary A; Kristensen G; Jackisch C; Joly F; Brown C; Le Fur N; du Bois A
    J Clin Oncol; 2010 Jul; 28(20):3323-9. PubMed ID: 20498395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.